Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | CASP2 | P42575 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261475 | 0.85 | CALCRL (0.47) | CALCRLHTR1A | |
| SCHEMBL261544 | 0.80 | CALCRL (0.32) | CALCRL | |
| SCHEMBL261366 | 0.80 | CALCRL (0.52) | CALCRLKDM4EALDH1A1KMT2ACASP3 | |
| SCHEMBL261453 | 0.79 | CALCRL (0.46) | CALCRLALDH1A1KMT2A | |
| SCHEMBL261349 | 0.78 | CALCRL (0.51) | CALCRLKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL261152 | 0.77 | CALCRL (0.35) | CALCRL | |
| SCHEMBL12429958 | 0.76 | KMT2A (0.32) | CALCRLKMT2A | |
| SCHEMBL261480 | 0.76 | AHR (0.31) | — | |
| SCHEMBL261482 | 0.74 | KDM4E (0.31) | KDM4E | |
| SCHEMBL261357 | 0.73 | CALCRL (0.49) | CALCRLKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-7696192-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696192-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1793827-B1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | MERCK & CO., INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | MERCK & CO., INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | CALCRL 2/4885KDM4E 3988/4885ALDH1A1 1122/4885 |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | CALCRL 2/4885KDM4E 3988/4885ALDH1A1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.